Background: Determining the prevalence of fatigue among cancer patients is complicated by the high prevalence of fatigue symptoms in the general population. The aim of this study was to determine the prevalence, severity and correlates of fatigue among both cancer patients and control subjects without cancer.
Introduction
Fatigue can be defined as the subjective sensation of having reduced energy, loss of strength or becoming easily tired. The symptom of fatigue is a common complaint among the general population [1] and among patients presenting in primary care [2] . It is also increasingly recognised as a troublesome problem in patients with cancer [3] . Its prevalence among such patients has been estimated to vary between 33% [4] and 100% [5] depending upon the assessment instrument used and the population studied. It has been described as a major complication of chemotherapy [6, 7] , radiotherapy [5, [8] [9] [10] and biological therapies [11] . It has a negative impact on self-care abilities [6, 9, 12] and on global quality of life [13] .
Unfortunately, few studies in this area have included control groups and this makes the interpretation of results rather difficult. Simply reporting the proportion of cancer patients who have 'felt fatigued' in the last week, is virtually meaningless without information about the proportion of 'normal healthy adults' who have felt the same. Those studies that have included control groups have produced conflicting results.
Several studies have found no difference in fatigue levels between cancer patients and subjects without cancer [14] [15] [16] [17] [18] [19] [20] [21] . Some of these studies were longitudinal, and although they found no differences between groups at baseline, they did report an increase in fatigue levels among patients after radiotherapy or chemotherapy [15, 16] . One of the largest of these studies was undertaken by Smets et al. [17] . They reported the development of the Multi-dimensional Fatigue Inventory (MFI-20) in a heterogeneous group of cancer patients receiving radiotherapy. They found no significant differences in 'general fatigue' levels between cancer patients and soldiers in training, junior doctors, psychology students or medical students. A subsequent study by Smets' group [20] reported that cancer patients, nine months after completing radiotherapy, were no more fatigued than control subjects without cancer. Taken together these studies might suggest that cancer patients not actively receiving anti-cancer therapy are no more fatigued than individuals without cancer. Another possible explanation is that the patients in these studies had become accustomed to feeling fatigued over a period of weeks or months and had re-set their internal standards to a lower level (a socalled 'response-shift' bias). In contrast to these 'negative' studies, Jacobsen et al. [22] reported that fatigue levels in breast cancer patients were higher than fatigue levels in controls both before and after adjuvant chemotherapy. Further work by Smets' group [20, 23] investigating radiotherapy related fatigue reported that baseline fatigue scores among cancer patients were significantly higher than mean fatigue scores in a control group of non-cancer volunteers. Andrykowski et al. [24] reported that patients with breast cancer who had been treated with radiotherapy a mean of 28 months previously were more fatigued than patients with benign breast problems. Both Bruera [25] and Stone [26] have reported that fatigue levels among patients with advanced cancer are significantly greater than fatigue levels among controls.
If cancer patients do experience more fatigue than the general population, as these latter studies suggest, then what is its cause? Fatigue may be due to the underlying cancer itself, in which case one might expect that different cancers would have different fatigue-inducing effects. In a study involving 499 patients with heterogeneous cancers Glaus [27] found a significant difference in physical fatigue between all cancer types (P < 0.005). Fatigue was highest in patients with lung cancer and lowest in patients with gynaecological cancers. Physical fatigue was significantly correlated with stage of disease. The highest level being in metastatic disease, followed by localised disease and disease in remission.
Although some relationship appears to exist between cancer related fatigue and the type and stage of malignancy, these factors alone cannot explain most of the variation in fatigue between individuals. Cytokines [28, 29] , cachexia [30] , abnormal muscle functioning [31] , anaemia [32, 33] , physical deconditioning [34] , psychological distress [25] or the severity of other symptoms [23] have all been suggested at one time or another as possible causes for cancer-related-fatigue. Aistars [35] has hypothesised that prolonged stress is the major cause of fatigue in cancer patients. She identified physiological, psychological and situational factors that may result in fatigue by causing constant physical and mental stress.
The primary aim of our study was to determine the prevalence of fatigue in different groups of cancer patients relative to a control group of elderly volunteers without cancer. A secondary aim was to investigate the correlates of fatigue in order to generate hypotheses about its aetiology. Adopting the theory of 'stress-related' fatigue proposed by Aistars we decided to investigate both physical (diagnosis, stage, nutritional status, muscle function, haematological and biochemical indices) and psychological factors (anxiety, depression, the severity of other symptoms) that we felt may contribute to the overall stress experienced by cancer patients.
Patients and methods

Patients
The patients included in this study consisted of four distinct subgroups:
Patients with prostate cancer (n = 62)
These patients had all been recently diagnosed with prostate cancer (predominantly early stage) and were about to start hormone therapy.
Patients with breast cancer (n = 34)
All of these patients were about to receive radiotherapy for recently diagnosed breast cancer (in 33 of 34 this was post-operative, adjuvant radiotherapy).
Patients with non-small-cell lung cancer (n = 36)
These patients had all been referred for palliative chemotherapy for inoperable lung cancer.
Patients with advanced cancer (n = 95)
All of these patients had 'advanced' cancer and were inpatients under the care of a palliative care team. They had not received chemotherapy or radiotherapy (except single fractions) within the previous four weeks.
This paper deals with the results of the baseline assessments in the combined patient group (n = 227) Data relating to changes in fatigue over time in some of the subgroups have been reported elsewhere [26, 36] .
The subjects included in this research were a convenience sample recruited from the Royal Marsden NHS Trust (a specialist cancer hospital) and Edenhall Marie Curie Centre (a hospice). As near as possible they represented a consecutive series of eligible patients. However, in the absence of the principal investigator due to illness or holidays recruitment was suspended.
Control population
Control subjects (« = 98) were recruited from hospital volunteers organisations and the League of Friends at the participating centres. The control group was essentially a convenience sample, selected to match the anticipated age and gender profile of the patients with advanced cancer. These subjects were not known to have cancer.
Procedures
Measures of subjective fatigue
The primary measure of subjective fatigue in this study was the Fatigue Severity Scale (FSS) [37] . This is a nine-item self-report scale developed for use among patients with chronic illnesses (Figure 1 ). Scores can range between 9 (no fatigue) and 63 (maximum fatigue). The psychometric properties of the FSS were re-assessed as part of this study. The internal consistency was found to be highly satisfactory (Cronbach's alpha = 0.96 in patients and 0.88 in controls). Test-retest reliability was undertaken in 87 control subjects who completed two assessments a median of three weeks apart. The within subject standard deviation (measurement error) of the scale was 4.7 units, which is satisfactory.
Fatigue was also measured using the three-item fatigue sub-scale of the European Organisation for Research and Treatment of Cancer 30-item quality of life questionnaire (EORTC QLQc30) [38] -see below.
Other questionnaires
• The EORTC QLQc30 is a 30-item questionnaire that consists of five functional scales (physical, role, cognitive, emotional and social functioning), three symptom scales (fatigue, pain and nausea vomiting) and a number of single items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation, diarrhoea and financial difficulties). Subjects are asked to rate each item on a four-point scale (e.g. During the past week: "Have you had pain?' Not at all, a little, quite a bit, very much). Scores are then transformed onto a 0-100 scale; a higher score represents a higher (i e., 'better') level of functioning, or a higher (i.e., 'worse') level of symptoms.
• The Hospital Anxiety and Depression Scale (HADS) [39] -this is a 14-item screening tool. It consists of separate scales for anxiety (HADA) and depression (HADD) a total score can also be generated (HADT). Scores on each sub-scale can range between 0 (no symptoms of depression/anxiety) to 21 (numerous and severe symptoms). When the scale is used as a screening tool a cut-off score of 11 or greater on either sub-scale is taken to indicate a 'probable case' of anxiety or depression [40] . One of the questions on the depression sub-scale (item 8: 'I feel as if I am slowed down') may be construed as referring to fatigue and so to avoid confounding, this item was excluded from the analysis when correlations were sought with the FSS. This approach has previously been reported by Smets [41] .
Other assessments
Grip strength (GStrength) was determined with a hand held grip dynamometer (Takei, Japan) using the best recording from three attempts with the non-dominant hand. Muscle fatiguability was determined by asking subjects to squeeze the investigator's ringers tightly for 10 seconds and then to record a measurement on the dynamometer. This process was repeated nine times over a three-minute period. The proportional decline in strength at three minutes was expressed as the '3 minute grip fatigue' (3MinGFatigue). The speed of muscle recovery was assessed by asking subjects to register a maximal grip on the dynamometer at 1 minute after cessation of exercise. The ratio of this reading to the initial grip strength was expressed as the' 1 minute grip recovery strength' (IMinGRecov). The use of this exercise protocol in patients with advanced cancer has been described elsewhere [26] .
Nutritional status was determined by calculating the Body Mass Index (BMI) from the subjects' height and weight. The Mid Arm Muscle Circumference (MAMC) was calculated [42] from the mid arm circumference and the triceps skin-fold thickness (measured using Harpenden skin-fold thickness callipers, UK). Other information recorded included subjects' age. sex, diagnosis, stage of disease, use of concomitant medication and Eastern CoOperative Oncology Group (ECOG) performance status (range 0-4; 0 = fully mobile, 4 = bed-bound, completely dependent).
For logistical reasons voluntary muscle function and nutritional status were not assessed in the breast cancer group.
Statistical methods
Measurement scales could typically only take a defined number of discrete values, non-parametric methods of analysis were therefore employed, e.g., correlation was assessed using the Spearman rank correlation coefficient (Rs) and the Mann-Whitney test was used for comparing groups. The calculation of Spearman's rank correlation included a correction for ties [43] . Multiple regression analysis was used to identify subsets of factors that were independently predictive of fatigue. Analysis was undertaken using the MINITAB program (Minitab inc., State College, PA 16801-3008, USA).
In order to determine the relationship between disease burden and fatigue severity it was necessary to broadly categorise the patients according to the extent of their disease. Cancer staging is diseasespecific and in order to code patients for their disease burden in a manner that was amenable to analysis across the different disease categories it was necessary to develop an ad hoc scoring system (Table 1) . Although this system has not been formally validated, it does appear at least to have face validity as a measure of the extent of disease burden.
Results
Control subjects
A total of 98 control subjects agreed to take part in the study. The median age of the subjects was 68 years (range 41-85), 37 of 98 (38%) were male and the overwhelming majority (>95%) were white. Half (49 of 98) of the controls reported the presence of at least one concomitant medical problem (e.g., arthritis, chronic airflow limitation or hypertension).
Severity of subjective fatigue
At least some degree of subjective fatigue was not an uncommon complaint among the volunteers, whether Abbreviations: E-Fatigue -EORTC QLQc30 fatigue sub-scale; E-PhysicalF -EORTC QLQc30 physical functioning sub-scale; HADA -hospital anxiety and depression anxiety sub-scale, HADT-8 -hospital anxiety and depression total score (without item 8); BMI -body mass index; MAMC -mid arm muscle circumference, 3MinGFat -3 minute grip fatigue. "P < 0001; b P < 001, c /> < 0.05. measured using the FSS or the EORTC Fatigue subscale (E-Fatigue). The median FSS score for the group was 20 (9-51) and the 95th percentile of scores was 42. We felt that it would be useful to define a conventional 'cut-off' for fatigue severity such that individuals who scored greater than this should be considered to have 'severe fatigue'. We decided to define 'severe fatigue' as a score on the FSS greater than that experienced by the 95th percentile of the control group (i.e., 5% of the control group were considered to be severely fatigued).
Correlates of fatigue
The results of the univariate analyses are shown in Table 2 . Fatigue severity was moderately to strongly correlated (Rs >0.5) with the total score, and the depression sub-score of the HADS and with the Role functioning sub-scale of the EORTC questionnaire (E-RoleF). On multivariate analysis, 22% of the variance Variables included in the analysis:
• Age, sex, diagnosis, presence of concomitant medical illness and use of concomitant medication (ECOG performance status was not included because it was felt to be more likely to reflect the consequences of fatigue than the causes of fatigue).
• All EORTC QLQc30 sub-scales with the exception of E-PhysF, E-RoleF, E-SoclF (excluded for the same reasons as the ECOG performance status).
• HADA, HADD-8 and HADT-8.
• MAMC and BMI.
• GStrength, lMinGFat and lMinGRecov.
in fatigue scores could be explained by the combination of a measure of psychological distress (HADT-8) and the presence of a concomitant medical problem (Table 3) .
Patients
A total of 227 patients completed a baseline assessment and were included in this analysis. The median age of the patients was 66 years (range 30-89), 127 of 227 (56%) were male and over 90% were white. A number of patients were taking either strong opioids (83 of 227, 37%) or corticosteroids (84 of 227, 37%).
Severity of subjective fatigue and prevalence of 'severe fatigue'
The median FSS score of the combined patient group was 40 (range 9-63) and this was significantly higher (P < 0.001) than that of the control group. The prevalence of 'severe fatigue' among the combined patient group was 48% (108 of 227).
Median fatigue scores varied considerably between the four sub-populations of patients; Breast cancer (median 24, range 9-61), Prostate cancer (median 24.5, range 9-50), Non-small-cell lung cancer (median 41.5, range 14-63) and Advanced cancer (median 54, range 9-63). The prevalence of 'severe fatigue' increased similarly (Figure 2 ), ranging from 15% in patients with breast cancer to 78% in patients with 'advanced cancer'.
The correlates of fatigue
On univariate analysis fatigue severity was significantly associated with both ECOG performance status (Rs = 0.71, 95% confidence interval (95% CI): 0.64-0.78, P < 0.001) and with 'disease burden' (Rs = 0.47, 95% CI: 0.36-0.57, P < 0.001). Fatigue severity was not related to patients' age. There was a weak association with gender (median FSSMALES = 39, median FSSFEMALES Table 4 . Multiple regression analysis in the patient group.
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Controls Breast Prostate NSCLC Advanced Figure 2 . Prevalence of 'severe fatigue' in different groups. 44 , P < 0.05). Patients on strong opioids or corticosteroids were more fatigued than patients who were not taking these drugs. Among those patients taking corticosteroids (n = 84) there was a significant relationship between dose of drug and fatigue severity (Rs = 0.31, CI: 0.10-0.50, P < 0.01). No such relationship between dose of drug and fatigue was found in the case of strong opioids (Rs = -0.03, CI: -0.25-0.20, P = ns). The results of the other univariate analyses are shown in Table 2 . Fatigue severity was moderately to strongly correlated (Rs > 0.5) with the measures of psychological distress, pain, dyspnoea, anorexia and global quality of life. On multivariate analysis 56% of the variance in fatigue scores could be explained by the combination of dyspnoea (E-Dyspnoea), a measure of psychological distress (HADT-8), pain (E-Pain) and 'disease burden' (Table 4) .
Discussion
Fatigue is a common complaint among the general population. For this reason it is important to assess fatigue among cancer patients in relation to the background level in the community. Most previous studies into the prevalence of cancer related fatigue have simply relied upon reporting the number of patients who complain of any level of fatigue. Unfortunately such an approach usually produces a prevalence figure that is of little clinical relevance. In this study we found that 48% of a mixed group of cancer patients reported fatigue levels in excess of that reported by 95% of a control group. Among those patients with advanced cancer the prevalence was as high as 78%. One drawback of our study was that the patient groups were essentially convenience samples. Although there was no reason to Variables included in the analysis were the same as for the control subjects with the addition of the measure of overall disease burden.
suspect a systematic bias in patient recruitment, it is possible that the study subjects were not entirely representative of the wider patient population. In addition to investigating the prevalence of fatigue among different groups of patients we also investigated the correlates of this symptom. On univariate analysis a great many of the study variables were significantly correlated with fatigue severity. There was a significant association between fatigue severity and global quality of life in both patients and controls. However, the strength of the correlation was significantly greater among the cancer patients (Rs = -0.67) than the controls (Rs = -0.24). This suggests that although fatigue is an important contributor to quality of life in both health and disease, it has greater impact on well-being among cancer patients.
The most consistent associations were between fatigue and psychological distress. This relationship was significant among both patients and controls and on both univariate and multivariate analysis. This was not an altogether unexpected finding. Both Pawlikowska et al. [2] and Lawrie and Pelosi [44] found a strong correlation between scores on the General Health Questionnaire (a measure of psychiatric morbidity) and severity of fatigue among the general population in large community surveys. Similarly Bruera [25] , Blesch [45] , Morant [18] and Smets [41] have all found that depression correlates significantly with the degree of fatigue in cancer patients. The nature of the relationship between these two constructs is clearly complex. However, it does not appear to be a straight-forward cause and effect relationship. Visser and Smets [46] have reported that whereas fatigue tended to increase after radiotherapy treatment, depression tended to decrease.
Other symptoms were also significantly associated with fatigue severity. Among the patients, the strongest associations were with anorexia, dyspnoea, and pain. Two of these three variables (dyspnoea and pain) also appeared as significant explanatory variables in the multivariate analysis. This supports Aistar's suggestion that fatigue severity in cancer patients is related to the overall distress that they experience. The significantly weaker association between these symptoms and fatigue in the control group may simply be a reflection of the lower frequency of these symptoms among this population.
As expected, we found a significant association between fatigue severity and 'disease burden' in the study patients. A similar result has also been reported by Glaus [27] . Unfortunately none of the subgroups of patients in our study were large enough to perform a meaningful analysis of the relationship between fatigue and stage of disease within any particular diagnostic group. For this reason we developed an ad hoc scoring system of disease burden that could be used in patients regardless of diagnosis. That this scoring system has not been formally validated is a weak point of our study. Future studies should concentrate on examining the relationship between fatigue and stage of disease within particular diagnostic groups.
We had originally hypothesised that cachexia would be significantly associated with fatigue. These symptoms often coexist among cancer patients and are sometimes said to form a clinical syndrome of 'anorexia-cachexiaasthenia' [30] , In support of such an association we did find a significant correlation between fatigue and mid arm muscle circumference (MAMC) among the patients. However, the strength of the association was relatively weak and MAMC did not appear as a significant predictor of fatigue after a multivariate analysis had been undertaken. Our findings suggest that a clearer distinction between cachexia and fatigue needs to be established, and that fatigue should not routinely be attributed to weight loss in cachectic cancer patients.
Fatigue is a subjective sensation that is best measured using self-report instruments. For many patients, however, the symptom of fatigue is perceived as a physical sensation of loss of muscle strength and endurance. As part of this study we investigated the relationship between subjects' self-report measures of fatigue and objective tests of voluntary muscle function. Among control subjects we were unable to find any association between subjective fatigue and grip strength, grip fatigue or grip recovery. This was not entirely unexpected. Studies of patients with chronic fatigue syndrome have often failed to find a correlation between subjects' perceived ability to undertake exercise and their actual results on formalised testing [47] . However, in the patient population we did find a significant but relatively weak association between subjective fatigue and Grip strength (GStrength) and Grip fatigue after three minutes'exercise (3MinGFat). The relationship between subjective and objective physical fatigue in cancer patients has also been studied by Dimeo et al. [48] . They investigated 78 patients who were undergoing high dose chemotherapy. In a cross-sectional study they tested patients on an exercise treadmill and assessed subjective fatigue in the previous 24 hours using the Profile of Mood States. They found a significant but low (r --0.30, P < 0.01) correlation between VO 2ma x and subjective fatigue. One drawback with both this study and our own is that the measure of objective fatigue that was used, relied to some extent upon voluntary effort. It would have been interesting to investigate the relationship between subjective fatigue and involuntary muscle function, but this was beyond the scope of our study.
Fatigue in cancer patients is often attributed to anaemia, but the relationship between haemoglobin level and fatigue among such patients is not well understood. Less than half of the patients involved in this study had blood tests taken within one week of completing their other assessments (data not shown). Among this rather selected group of patients we found a weak but significant association between haemoglobin level and fatigue (n -121, Rs = -0.22, P < 0.05). Haemoglobin levels were not independently predictive of fatigue when a multivariate analysis was undertaken. However, it is possible that fatigue may be more related to changes in haemoglobin level than to any particular haematocrit. In support of this, studies of anaemic patients receiving erythropoietin therapy [32, 33] have reported that increases in haematocrit are associated with improvements in fatigue. Further work is required to identify the relative contribution of anaemia to the development of cancer related fatigue.
In conclusion, we have determined that subjective fatigue is a common problem for cancer patients and particularly for patients with advanced disease. We have identified a number of factors that are significantly related to the severity of fatigue. Four of these factors were able to predict 56% of the variance in fatigue scores among the patients. Further work is required to investigate whether these associations were co-incidental or causal. If the latter, then paying greater attention to managing pain, dyspnoea and depression may result in a concomitant improvement in the management of fatigue.
